Immunotherapy for pediatric osteosarcoma with lung metastases after resection shows positive data

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

In the phase II CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate CAR T-cell therapy in patients with high-risk smoldering multiple myeloma, all 20 patients were negative for minimal residual disease within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up.

April 24, 2026

Vol.52 No.16

Drugs & Targets

EU approves Ojemda as first targeted therapy in r/r pediatric low-grade glioma regardless of BRAF alteration

The European Commission has granted conditional marketing authorization for Ojemda (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with pediatric low-grade-glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies.

April 24, 2026

Vol.52 No.16

Cancer Policy

FDA issues reminder to sponsors: Disclose clinical trial results

FDA issued a stern reminder to medical product companies and researchers of the requirements to submit certain clinical trial results information to ClinicalTrials.gov.

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced the appointment of Salwan Al Mutar as director of Clinical Research at START Dallas-Fort Worth.

April 17, 2026

Vol.52 No.15

Clinical Roundup

ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

Patients with stage 3 colon cancer with deficient DNA mismatch repair had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq) was added to standard chemotherapy after surgery, according to a study by researchers at the Alliance for Clinical Trials in Oncology.

April 17, 2026

Vol.52 No.15

Clinical Roundup

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Patients with pancreatic cancer who received the experimental drug elraglusib, alongside standard chemotherapy, were twice as likely to be alive after one year of treatment, compared to those receiving chemotherapy alone, according to the results of a randomized phase II clinical trial conducted by researchers at Northwestern University. The drug also reduced the risk of death by 38%.

April 17, 2026

Vol.52 No.15

Immunotherapy for pediatric osteosarcoma with lung metastases after resection shows positive data

YOU MAY BE INTERESTED IN

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

EU approves Ojemda as first targeted therapy in r/r pediatric low-grade glioma regardless of BRAF alteration

FDA issues reminder to sponsors: Disclose clinical trial results

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Renew today!

Subscriber content

Never miss an issue!

Login